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The article is devoted to the comprehensive analysis of scientific, practical and legal issues of personalized medicine that is a rapidly 
developing science-driven approach to healthcare. It is concluded that there is lack of general legal framework for the encourage-
ment of scientific researches and practical implementation in this field. The article shows foreign experience and prospects for the 
introduction of personalized medicine as a key concept of healthcare system, which is based on a selection of diagnostic, thera-
peutic and preventive measures that would be the most effective for a particular person in view of individual characteristics. The 
conclusions and proposals to improve the current legislation and development of personalized medicine in Ukraine are suggested.
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The beginning of the XXI century is marked by the 
completion of a number of global projects that give 
hope for substantial progress in the field of in the field 
of medical issues, including oncology. Thus, in particu­
lar, decoding of the genome, identification of genetic, 
epigenetic and transcriptional changes in normal 
and tumor cells brings scientists and doctors closer 
to new opportunities in early diagnosis and targeted 
treatment of cancer patients. Recently, a special hope 
is focused on the identification of normal and tumor 
stem cells that can be a modern platform in persona­
lized approach for optimizing technology of diagnosis 
and treatment of patients. However, the successful de­
velopment of the new vector of the medicine requires 
not only deep fundamental research and introduction 
of high technologies, but also parallel development 
and creation of the regulatory framework for their 
implementation.
The rapid pace of development the modern tech­
nologies requires the harmonization of scientific­
practical aspects and existing problems of medical law, 
which will bring timely access to the real possibilities 
of personalized medicine. This means that activity 
(including economic) in the field of medical practice 
requires careful legislative regulation in order to pro­
vide the population with high­quality and affordable 
personalized medical assistance. Personalized medi­
cine is such a model of health care based on a selection 
of diagnostic, therapeutic and preventive measures 
that would be best for a particular person in view of ge­
netic, physiological, biochemical or other individual 
characteristics. Personalized medicine is a direction 
of modern medicine that uses individually oriented 
targeted diagnostic and therapeutic approaches. The 
essence of personalized medicine is reduced to the 
fact that a person, and not a disease, is placed at the 
center of the process of treatment and medical skill. 
Especially this mechanism is inherent in the treatment 
of patients with oncological diseases. This is due 
to various reasons and background of the disease, 
which is also accompanied by changes in different 
genes that are completely individual in each case.
The right of citizens to health care, unlike other 
human rights, has recently become legally enshrined 
in legal acts, including in the constitutions of the coun­
tries of the world community. Oddly enough, until the 
middle of the last century, in the constitutions of states 
all over the world the right of citizens to health was 
not mentioned, although many other human rights 
had already been proclaimed. Due to the prominent 
law reform in the health sector in many countries the 
subject of the role of medical practice is beginning 
to change in collaboration with other members of the 
medical and organizational processes. The imple­
mentation of legislative innovations implies structural 
and organizational changes in the health care system, 
the introduction of new organizational and financial 
mechanisms, ensuring economic independence, and 
increasing the diversity of organizational and legal 
forms of medical organizations.
In the policy of the Health 2020 program, the overall 
goals are a significant improvement in health and an in­
crease in the welfare of the population, reduction of in­
equalities in health care, strengthening of public health 
and providing the availability of sustainable health sys­
tems tailored to individual needs of people. Such sys­
tems should be characterized by high quality of care 
and the principles of total coverage of medical care, 
social justice and sustainability. However, two main 
strategic objectives of the policy are to improve health 
for all people and to reduce inequalities with regard 
to health. Reducing inequities in health is achieved 
through the impact on the social and environmental 
determinants of health [1]. Albeit, despite the declared 
state’s importance of implementing systemic and 
integrated health care reform, the Ministry of Health 
of Ukraine (the central executive body, which ensures 
the formation and implementation of state policy in the 
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field of health care) works in this direction in extremely 
unsystematic way. For the successful implementation 
of the principles and mechanisms of the new European 
Health Policy 2020 in Ukraine, justification and deve­
lopment of a national strategy and program is neces­
sary. It is advisable to direct the new national health 
policy in Ukraine to the implementation of strategic 
priorities in the field of preservation and strengthen­
ing of health, prevention of chronic non­infectious 
(especially oncological) diseases, minimization of the 
influence of risk factors of disease development on the 
basis of a cross­sectoral approach, creation of a favor­
able for health Environment, formation of responsible 
attitude of citizens to personal health and motivation 
of the population to a healthy lifestyle.
In such conditions, special attention should be fo­
cused on the issue of optimizing the organization and 
financing of the medical sector with the creation 
of an effective system of public health protection, 
through the priority development of primary health 
care, family medicine, personalized medicine, which 
are able to provide medical needs of the population 
at the level of current standards, taking into account 
the fundamentals of personalized medicine. After 
signing in 2014 of the Association Agreement with 
the European Union [2], electing Ukraine’s European 
integration vector must ensure gradual forthcom­
ing to European standards in the health care system 
through a reform aimed at creating a system focused 
on the patient, able to provide medical care for all 
Ukrainian citizens at the level of developed European 
states. The guideline for the reform was the European 
Union’s “European Health Strategy 2020” program [3]. 
According to calculations of specialists, by 2020 the 
number of new cancer patients in Ukraine will exceed 
200 thousand [4].
Our aim is to conduct a comprehensive analysis 
of theoretical, scientific and legal problems of imple­
mentation of personalized medicine in Ukraine.
According to Genomics and Personalized Medicine 
Act of 2010 the term “personalized medicine” means 
any clinical practice model that emphasizes the sys­
tematic use of preventive, diagnostic, and therapeutic 
interventions that use genome and family history in­
formation to improve health outcomes [5].
Although in recent years, there has been significant 
progress in clinical oncology: with the development 
of new antitumor drugs with targeted molecular ac­
tion, the contingent of patients who receive effective 
specific therapy has improved their quality of life, but 
despite their success, cancer mortality remains high. 
At the same time, the empirical choice of the treatment 
regimen, the lack of selectivity and limited effective­
ness of many antitumor drugs, a large number of side 
effects, as well as the high cost of therapy imply seri­
ous responsibility of the doctor. That is why the need 
for individualization of treatment becomes a topical 
issue in contemporary Ukraine, since knowledge of the 
molecular and genetic characteristics of the tumor 
and the patient will allow the personalization of thera­
peutic regimens and reduce the risk of manifestations 
of toxi city of chemotherapeutic agents: an individual 
approach involves administering to a specific patient 
the required preparation in an adequate dose for certain 
indications in an effective period of time. Even with the 
rapid development of a new generation of anticancer 
drugs with targeted selective action — targeted drugs 
are designed to inhibit the growth, proliferation and vi­
ability of tumor cells through specific interactions with 
one or more target proteins. In this case, under the 
conditions of formally known molecular targets for each 
target drug, the response of the patient to treatment 
remains more individual and unpredictable. Therefore, 
the main task in oncology remains the choice of the 
most effective personalized treatment, which until now 
remains the mostly experimental.
“Personalized medicine is the dream of every on­
cologist and the legitimate expectation of every can­
cer patient”, says Professor Martine Piccart, ESMO 
President. “However, currently we are not yet in the 
era of personalized oncology but in the era of stratified 
oncology, which means we are able to classify cancers 
according to critical targets against which we hope 
to develop effective drugs. Modern technologies such 
as deep DNA sequencing will be powerful tools in the 
future allowing us to identify drugable mutations” [6].
There is no official definition of personalized 
medicine in the European Union. But for the purpose 
of the European Commission report (31 October 2013) 
personalized medicine refers to a medical model 
using molecular profiling for tailoring the right thera-
peutic strategy for the right person at the right time, 
and/or to determine the predisposition to disease and/
or to deliver timely and targeted prevention [7].
America’s legislation is more developed in this 
area. On May 27, 2010, in the House of Representa­
tives, an A Bill with the aim to secure was adopted the 
promise of personalized medicine for all Americans 
by expanding and accelerating genomics research 
and initiatives to improve the accuracy of disease 
diagnosis, increase the safety of drugs, and identify 
novel treatments, and for other purposes.
Signed into law by the President on December 13th, 
2016, the Act passed the House of Representatives 
(392­26) and Senate (94­5) with overwhelming bipar­
tisan support. The Act secures $4.8 billion in funding 
for the necessary infrastructure to advance precision 
medicine. This includes funding to the National Insti­
tutes of Health to support the President’s Precision 
Medicine Initiative ($1.5 billion) and to Vice President 
Biden’s “Cancer Moonshot” initiative ($1.8 billion). 
Spending under the Act will advance precision medi­
cine more specifically by developing [8].
Can we find an analog of normative­legal regulation 
in the domestic legislation? Unlikely. Moreover, even 
none of the Concepts of the Ministry of Health does 
not foresee the movement of the health care system 
in Ukraine towards personalized medicine. Personal­
ized medicine is a rapidly developing science­driven 
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approach to health care. So does it need a specific 
legislation to regulate such social relationships?
Success in the treatment of cancer patients can 
be achieved in many respects only due to the success­
ful combination of modern science­intensive technolo­
gies, regulated by legislation. However, unfortunately, 
deep knowledge of the nature of the malignant process 
is not always used in a timely manner in clinical practice 
because of the lack of necessary legal norms.
In what area should Ukrainian legislation be de­
veloped: medical or scientific and technical? Obvi­
ously, it will be impossible to restrict one normative 
legal act that would regulate the whole set of social 
relations in the field of personalized medicine, but 
there should be a key program document that will 
define the main concepts, principles, directions, and 
stages of the implementation of personalized medicine 
in Ukraine. In the future, the regulatory system should 
be formulated in a complex way, improving the current 
or developing a completely new legislation, whose fun­
damental task should be adequate protection: scien­
tific development, medical secret, personal data, etc. 
The necessity of special regulatory regulation is also 
that in its absence it is impossible to realize scientific 
achievements in this sphere and to implement them 
in real medical practice, what is the urgent problem 
of the present.
Claiming to introduce the basics of personalized 
medicine, it is necessary to conduct in­depth analysis 
and refinement of the algorithm using a huge arsenal 
of basic and clinical knowledge. For the full implemen­
tation of the foundations of personalized medicine 
in Ukraine there is also a need for the proper regula­
tion of corresponding social relations. Legislation 
should comprise and cover the following elements 
(components):
•	An adequate level of protection of intellectual 
property rights for scientific developments, which 
are the driving force for the formation of personal­
ized medicine. Medical diagnostics and genomic 
medicine are the key tools for many personalized 
therapies. In this regard, there are issues of intel­
lectual property rights that need to be addressed. 
So, the world practice goes in such a way that the 
application for a patent for the diagnostic method 
should undergo even more careful analysis and 
verification. For example, in Mayo, the Supreme 
Court (the decision Mayo Collaborative Services 
v. Prometheus Labs., Inc.) determined that certain 
diagnostic analysis — such as a diagnostic test that 
correlates to a patient’s health or disease — is not 
patentable when only the correlation between the 
diagnostic reading and the health status of the 
patient is the subject of the patent. The Supreme 
Court unanimously held that broadly claimed di­
agnostic methods are not patent­eligible because 
they attempt to patent a law of nature. As a result, 
patent applications claiming diagnostic methods 
are now more critically examined for patent­eligi­
bility as well as novelty and non­obviousness [9]. 
In addition, the question arises about the ownership 
of genetic information.
•	IT implementation, which will guarantee the security 
of personal data, the preservation of medical se­
crets, and the provision of high security standards 
for electronic health data. There is should be a bal­
ance between facilitating the exchange of medical 
records among health care providers and public 
health officials and the need to ensure the privacy 
of personal medical information.
•	The foundation for protecting medical and genetic 
information, including a guarantee of non­discrimi­
nation based on the results of laboratory and other 
research, treatment, etc., including clinical and 
genetic research. For example, the Genetic Infor­
mation Nondiscrimination Act of 2005 (GINA) [10] 
prohibits:
— medical insurance companies from discrimi­
nating against applicants on the basis of their 
genetic information;
— medical insurance companies from request­
ing that applicants for health coverage plans 
be genetically tested;
— employers from using genetic information 
to refuse employment and from collecting 
such data.
•	A reliable mechanism for protecting the pa­
tient’s rights to effective treatment with the corre­
sponding responsibilities of the doctor to conduct 
appropriate diagnosis and therapy.
•	Reform of state regulation of the health care system 
and elements of health insurance with maximum 
consideration of the above information, in particu­
lar the direction of the entire system for disease 
prevention and its diagnosis, which will significantly 
reduce the cost of treatment in the future, as well 
as stimulate and develop public­private partner­
ships.
According to expert estimates, about 250 variants 
of the tumor disease are differentiated based on only 
etiological, pathogenetic, organo­ and tissue­specific 
features, symptomatic and prognostic course of the 
pathological process. In this case, the patient’s re­
sponse to the use of standard regimens and modes 
of administration of drugs, depending on the genetic 
constitution of the body, is accompanied by significant 
fluctuations in the effectiveness and safety of the 
therapy. For example, the frequency of development 
of unwanted drug reactions or even death in some 
countries goes to the 4–5th place among all its causes. 
In addition, numerous pharmacoepidemiological 
studies indicate a complete lack of efficacy of drug 
therapy in 40% of patients. The individual variability 
of the body’s reactions to medication can fluctuate 
within 20–95%, the lack of response to pharmaco­
therapy — 10–40%, the rate of excretion of drugs 
in different patients differs 4–40 times, the metabolism 
of drugs — 10–100 times [11].
The factors that determine the response to the 
drug and affect the changes in the body’s reaction are 
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complex and function in combinations, some of which 
include the basic aspects of human biology, since 
a certain response to a drug directly affects the nature 
and life expectancy. Genetic variability is recognized 
as an important determinant of the individual variability 
of the drug response from clinical observations of the 
late 1950s (Kalow et al., 1957; Evans et al., 1960). 
Observing that the individual variability of the re­
sponse to antitumor agents is often greater among the 
members of the population, compared to one person 
at different times, further emphasizes heredity as the 
main determinant of the response to the drug (Vesell, 
1989; Kalow et al., 1998). These clinical and population 
data contributed to the formation of pharmacogenetics 
in the direction of assessing the genetic contribution 
to the individual variability in drug therapy [12].
Individual testing of tumor response in cancer 
treatment includes ex vivo tests that are important for 
predicting individual responses to the therapy. Such 
tests are developed on the basis of the response of the 
tumor cells to specific anticancer agents in vitro, which 
characterizes the sensitivity or resistance to a certain 
exogenous factor [13]. Previous studies have shown 
positive or negative aspects, peculiarities of applica­
tion and limitation, and other properties and problems 
of such ex vivo analyzes. Indeed, there are a number 
of conceptual problems that do not depend on the 
chosen model for identifying an experimental model: 
an adequate choice of drug concentration relevant 
to the clinical situation; primary tumor or metastasis, 
heterogeneity of the tumor; the ability to maximally 
simulate the tumor microenvironment ex vivo. It is obvi­
ous that between the response of the patient to treat­
ment and inhibition of tumor growth in vitro is a rather 
complex relationship [14], but despite this, numerous 
studies have achieved positive results for patients: 
more quick response to therapy, increasing longevity, 
reducing the number of chemotherapeutic treatment 
lines and side effects and reducing the cost of treat­
ment [13]. Finally, some authors demonstrated 78.4% 
sensitivity and 90.1% specificity of individual tumor 
response testing [13, 15].
An important breakthrough in the sense of ini­
tiation and progression of cancer was the discovery 
of a cell subpopulation with features of stem cells, 
commonly referred to as cancer stem cells (CSC), 
a critical factor for a tumor. Most of the authors con­
sider them responsible for the phenomenon of resis­
tance to antitumor agents and disease progression 
[16, 17]. Because of the presence of resistant CSC 
clones, each time in the treatment of the patient there 
is a variant of subsequent relapse of the tumor, which 
will be different, most likely, more resistant to therapy 
[18]. Undoubtedly, the choice of effective therapy 
is extremely important not only at the beginning of the 
treatment process, but also in the context of the 
progression of the disease, that is why the research 
on the most informative prognostic biomarkers, in­
cluding markers, associated with the CSC phenotype, 
is extremely important. The targeting of anti­CSC 
therapy is a new paradigm in the treatment of cancer, 
which is one of the key tasks and areas of personal­
ized medicine. Recently there was developed a new 
test that involves analyzing tumors for the CSC and 
parallel study of sensitivity to anticancer drugs — 
ChemoID® [19–21]. Studies conducted using this 
test showed that patients with the same stage and 
other characteristics of the tumor process differ 
significantly in the clinical response to treatment, 
which also indicates the need for “personalization” 
in the diagnosis and treatment of cancer patients 
with a special approach to the identification and detail 
of tumor cells with CSC phenotype.
Thus, the concept of personalized medicine in­
cludes the use of clinical, genomic, transcriptional, 
proteomic and other information sources for the 
construction of an optimal algorithm for a person 
in terms of risk assessment, prevention and treatment: 
personalized medicine causes the rejection of the 
“protocol/standard” model of medicine characterized 
by empirical and “averaged” data [22]. In addition, 
understanding the “molecular portrait” of a person 
that causes specific properties in susceptibility to the 
disease, its progression and response to treatment will 
lead to the adaptation of medical care to the require­
ments of each individual patient [23].
By the time of the personalized medicine, the 
diagnosis of the tumor process, the prognosis of the 
course of the disease and the subsequent treatment 
were based on histological parameters, including the 
tissue origin and stage of differentiation. Experience 
has shown that morphological classification is often 
of little information and “scarce” in many aspects, 
since patients with the same histological diagnosis 
may have different responses to therapy and different 
course of the disease. Now we see the accumulation 
of vast amounts of data on molecular, genetic, epi­
genetic and other biomarkers of tumor development 
obtained by highly specific modern methods that are 
supported by new developments in computer systems 
analysis. Personalized medicine is a revolutionary 
concept that challenges the traditional fundamen­
tal and clinical oncology. Although the transition 
to personalized medicine requires a sufficiently large 
initial investment, in the long run such a direction will 
increase the profitability of future medical practice. 
The choice of cancer therapy today is usually based 
on prognostic factors, as well as on the experience and 
intuition of the doctor, but is associated with the risk 
of error in the treatment of a particular patient, which 
reduces the effectiveness of treatment, increases its 
cost and may even lead to tragic consequences. At the 
same time, the extremely significant disadvantage 
of modern antitumor therapy is the high cost of drugs, 
which also indicates the promise of a personified ap­
proach in the management of cancer patients, in terms 
of determining the sensitivity of the tumor of the patient 
to specific antitumor agents, thereby reducing the 
cost of treatment by a reasonable and adequate use 
of high­cost drugs.
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Personalized medicine has potentially significant 
benefits for patients, clinicians and health care sys­
tems alike. Some potential advantages offered by this 
new approach include:
•	ability to make more informed medical decisions;
•	higher probability of desired outcomes thanks 
to better­targeted therapies;
•	reduced probability of adverse reactions to medi­
cines;
•	focus on prevention and prediction of disease 
rather than reaction to it;
•	earlier disease intervention than has been possible 
in the past;
•	improved health care cost containment [7].
Thus, today there is no definitive solution to the 
issues and problems for all types of cancer, but it be­
comes clear that personalized medicine is very impor­
tant for patients and hospitals, and such “personaliza­
tion” requires the humanization of medicine and begins 
with an individual doctor/patient relationship [6]. 
The perspective of the introduction of personalized 
medicine depends on the multidisciplinary approach: 
a team of doctors, experts, lawyers, legislators who, 
in teamwork and caring for the patient, will make real­
istic personalized medicine that will potentially improve 
the effectiveness of therapeutic strategies for cancer 
patients and increase their life expectancy to improve 
its quality. Although this poses a lot of problems in the 
organization of medical care, it is a necessary way 
to effectively treat each individual patient.
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